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Abstract
Even though WHO has approved global goals for hepatitis elimination, most countries have yet to
establish programs for hepatitis B and C, which account for 320 million infections and over a mil-
lion deaths annually. One reason for this slow response is the paucity of robust, compelling analy-
ses showing that national HBV/HCV programs could have a significant impact on these epidemics
and save lives in a cost-effective, affordable manner. In this context, our team used an investment
case approach to develop a national hepatitis action plan for South Africa, grounded in a process
of intensive engagement of local stakeholders. Costs were estimated for each activity using an
ingredients-based, bottom-up costing tool designed by the authors. The health impact and cost-
effectiveness of the Action Plan were assessed by simulating its four priority interventions (HBV
birth dose vaccination, PMTCT, HBV treatment and HCV treatment) using previously developed
models calibrated to South Africa’s demographic and epidemic profile. The Action Plan is esti-
mated to require ZAR3.8 billion (US$294 million) over 2017–2021, about 0.5% of projected govern-
ment health spending. Treatment scale-up over the initial 5-year period would avert 13 000
HBV-related and 7000 HCV-related deaths. If scale up continues beyond 2021 in line with WHO
goals, more than 670 000 new infections, 200 000 HBV-related deaths, and 30 000 HCV-related
deaths could be averted. The incremental cost-effectiveness of the Action Plan is estimated at
$3310 per DALY averted, less than the benchmark of half of per capita GDP. Our analysis suggests
that the proposed scale-up can be accommodated within South Africa’s fiscal space and represents
good use of scarce resources. Discussions are ongoing in South Africa on the allocation of budget
to hepatitis. Our work illustrates the value and feasibility of using an investment case approach to
assess the costs and relative priority of scaling up HBV/HCV services.
Keywords: Disease control, costs, impact, health planning, cost-effectiveness analysis, developing countries, international health
policy, planning, policy implementation
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Introduction: the opportunity and policy barriers
to scaling up HBVand HCV treatment
With the advent of new and highly effective cures for hepatitis C
(HCV) and an expanding array of preventive and therapeutic inter-
ventions for hepatitis B (HBV), there is growing interest among gov-
ernment, advocacy and international partners to mount large-scale
national hepatitis control programs. These programs could dramati-
cally reduce the burden of HBV and HCV, which together account
for >320 million infections and over 1.24 million deaths annually
(World Health Organization 2017). Although ambitious global and
regional hepatitis goals exist, notably the elimination of HBV/HCV
by 2030 championed by WHO (World Health Organization
2016a), most countries have yet to establish comprehensive national
programs to scale up HBV and HCV prevention and treatment.
One reason for the slow action is the paucity of locally informed
rigorous analyses estimating the likely cost, health impact, value and
feasibility of scaling up national HBV/HCV programs. In addition,
there is no immediately available source of large-scale external
donor aid for HBV/HCV programs. LMIC countries contemplating
HBV/HCV program scale-up will need to focus on mobilizing
domestic financial resources for which many other health priorities
compete. Under these circumstances, modelling studies of prospec-
tive HBV/HCV investments will have to show that hepatitis should
be a priority for domestic financing, and these analyses will need to
be directed at countries’ ministries of finance and health, national
health insurance agencies, and other payer institutions.
In this context, our team, composed of leading South African
experts and Ministry of Health officials and outside specialists in
global health policy and economics, used an investment case
approach to design a 5-year National Hepatitis Action Plan for
South Africa. This Action Plan assessed the technical and financial
feasibility of investments in an expanded HBV/HCV prevention and
treatment program that would launch the country on a longer-term
trajectory towards possible elimination of HCV and major reduc-
tions in the burden of HBV and HCV (Schwartla¨nder et al. 2011).
This approach was also grounded in a process of intensive engage-
ment of local stakeholders, with national technicians, senior govern-
ment officials and advocates all heavily involved.
The purpose of this article is to describe the process of develop-
ing this Action Plan, present its main methods and results, and eluci-
date the policy implications of our work for South Africa and other
countries. We view this paper as providing a pioneering real-world
example for other countries that will also soon be embarking on the
road to HBV/HCV national program scale-up.
Epidemiology of HBV and HCV in South Africa
Like many low- and middle-income countries (LMICs), South Africa
suffers from a significant burden of HBV and HCV, with over
113 million disability-adjusted life years (DALYs) lost due to hepati-
tis in 2013 (Stanaway et al. 2016). In a recent systematic review
based on observational studies performed in the general population,
healthcare workers and pregnant women, HBsAg seroprevalence
was estimated at 6.7%, pointing to high intermediate endemicity
with an estimated 3.5 million individuals chronically HBV infected
(Schweitzer et al. 2015). While HCV seroprevalence and identifiable
risk factors in South Africa are still poorly understood and are being
characterized through a number of studies (Scheibe et al. 2017), it is
currently estimated that just under 1% of the population are chronic
carriers of HCV infection (around 400 000 persons) (Ellis et al.
1990).
While these numbers are dwarfed by the roughly 12% of
South African adults infected with HIV, the burden of liver disease
due to HBV and HCV is significant. The lifetime risk of cirrhosis,
liver failure and hepatocellular carcinoma is 15–40% for HBV
patients and the risk that chronic HCV patients become cirrhotic
within 20 years is 15–30%. Each year these HCV patients have
a 1–4% risk of developing hepatocellular carcinoma (WHO
Africa Regional Office 2016). Most of these people living with
HBV and HCV do not know that they are infected, placing them
at risk for liver-related morbidity and mortality and increasing
the likelihood that they will spread the virus to others (Tre´po
et al. 2014).
South Africa National Hepatitis Action Plan
In the face of this large burden and stimulated by the prospect of
new cures for HCV, the South African Department of Health
(NDoH) drafted new clinical guidelines for viral hepatitis in 2015–
Key Messages
• Hepatitis B and C (HBV/HCV) have significant burdens globally and nationally, accounting for >300 million infections
and over a million deaths annually worldwide. Despite the advent of new cures for HCV, an expanding array of preven-
tion and treatment options for HBV, and the adoption of ambitious global HBV and HCV targets, few countries have
designed or embarked on program scale-up to date.
• South Africa’s 5-year National Hepatitis Action Plan is one of the first examples of an investment case that combines
tools for costing, impact modelling, cost-effectiveness analysis, and fiscal space analysis for scaled-up HBV and HCV dis-
ease control scenarios.
• The South Africa Action Plan investment case shows that carefully selected investments in HBV and HCV can have a sig-
nificant impact on the twin epidemics, while meeting standard cost-effectiveness criteria and demonstrating affordability
amidst government expenditure constraints.
• The South Africa Action Plan experience also shows the importance of an engaged multi-stakeholder process that
involves the finance and health ministry and other national interest groups.
• The investment case approach used in South Africa can be adapted to other contexts and can guide other countries
looking to synthesize and analyse the evidence needed to consider the advisability of embarking on large scale invest-
ments in HBV/HCV.
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2016, with the backing from the World Health Organization
(World Health Organization 2016b, c). To translate these guidelines
into an operational implementation plan, NDOH, in collaboration
with this paper’s authors, developed a ‘Viral Hepatitis National
Action Plan’ for the 5-year period 2017–2021.
In creating the Action Plan, South Africa sought to answer the
following key questions:
1. What set of priority interventions should be included in a hepati-
tis national program?
2. How much would these investments cost over an initial 5-year
period, assuming it would eventually take more than a decade to
eliminate HCV and control HBV?
3. If little or no external funding was available and if such a plan
had to be financed entirely from domestic public sources, would
this be affordable?
4. Would the planned investments represent good value for money
for South Africa, given its limited budget resources and many
competing demands?
5. Overall, would the combination of spending, impact and pro-
jected cost-effectiveness add up to a strong ‘investment case’ to
present to the National Treasury (NT), the South African finance
ministry?
The investment case approach
This investment case approach has been widely used in other areas
of health, including in assessing proposed investments in national
HIV, TB and malaria programs (Schwartla¨nder et al. 2011), but it is
in the nascent stages of being applied to HBV and HCV. HCV scale-
up has been costed for Georgia, Egypt and Mongolia (Estes et al.
2015).
Impact of HCV treatment has been estimated for >50 countries
using an approach pioneered by the Center for Disease Analysis,
comparing the status quo with the WHO goals of elimination by
2030 (Razavi et al. 2014; Bourgeois et al. 2016; Hajarizadeh et al.
2016; Soipe et al. 2016). In addition, the projected impact and cost-
effectiveness of interventions for HBV have recently been modelled
in China and for HCV in India (Aggarwal et al. 2003; Nayagam
et al. 2016a; World Health Organization 2016a), but there are few
if any comprehensive investment cases. Our work in South Africa is
one of the first attempts to produce such a national investment case.
Methods and data
Scope
The first step was for our team, composed of South African NDoH
officials, local hepatologists, and experts in epidemiological model-
ling, heath economics and financing, to establish the scope and
organizing framework for the Action Plan. Using the draft national
guidelines, we developed a list of HBV and HCV activities that the
NDoH Task Force agreed should be included, and then grouped
these activities into thematic categories (‘priority areas’). Since the
scope of the Action Plan covered a wide range of HBV/HCV preven-
tion and treatment activities, plus improved surveillance, provider
training and health communications/demand generation, we con-
sulted >20 South African experts to gather inputs. For each activity,
we considered factors including: current level of implementation,
feasible rate of scale-up, targets for the 5-year period, prices and
unit costs, organizational unit responsible for implementation, as
well as contextual factors such as geographical variation or legal
and regulatory requirements.
Cost and affordability
To estimate the Action Plan’s financial requirements, we created an
ingredients-based costing tool. In doing this, we drew upon standard
methods which have been used to cost other programs such as the
South Africa HIV Investment Case and the National HIV, TB and
STI Strategic Plan (UNAIDS; Asian Development Bank 2004; South
Africa National Department of Health; South Africa National AIDS
Council 2015, 2017).
The tool was implemented in Microsoft Excel and provides tem-
plates for program objectives, planned activities, responsible parties,
scale-up targets and progress indicators. No primary costing was
undertaken, but key stakeholders and service providers were inter-
viewed to obtain the required cost data from existing secondary
sources such as reference price lists, expenditure records and prior
costing studies.
The tool summarizes costs by objective, activity and calendar
year, and breaks down capital, recurrent, fixed, variable and one-
time start-up costs. Furthermore, it distinguishes ‘additional funds’
(e.g. HCV medications) from ‘reallocated existing resources’ (e.g.
time spent by nurses doing counselling and care for hepatitis
patients).
The costing approach was from the perspective of the service
provider. Available unit costs were multiplied by the estimations of
quantities from the epidemiological projections of the numbers in
need, which were guided by the annual targets over the 5-year
period. Unit prices (ZAR 2016) were assumed to be linear with
respect to scale, with no increasing or decreasing returns. Capital
investments were annualized over their useful life-years. The
exchange rate at end 2016 was used.
To assess affordability and domestic fiscal capacity, we com-
pared the estimated costs of the South Africa National Hepatitis
Action Plan with projected annual public-sector budgets for health,
looking at both total and incremental funds over the 5-year period,
and adjusting for anticipated inflation.
Health impact
To estimate the impact of these investments on the burden of disease
in South Africa, we adapted two well-known and widely-accepted
disease models.
For HBV, we used the model developed by Imperial College
London (Nayagam et al. 2016c) which operates dynamically and
projects the simultaneous impact of a range of HBV prevention
activities (newborn and child vaccination, prevention of mother to
child transmission, HBV treatment as prevention) and treatment
with anti-virals on number of new infections, cases of cirrhosis and
liver cancer, and HBV-related mortality. The model also allows for
the simulation of scenarios for scaling up HBV treatment gradually
by targeting treatment to individuals in particular demographic
groups (e.g. pregnant women, those in certain birth cohorts, etc.)
and those with more advanced stages of liver fibrosis.
For HCV, we used the CDA disease model, which links preva-
lence to screening in order to estimate the size of the screening and
diagnosis effort required, and then ties projected treatment with
direct acting anti-virals (DAAs) to reductions in chronic HCV preva-
lence, illness and mortality (Blach et al. 2017). This static Markov
model assumes constant new infections into the future and does not
include a dynamic loop connecting HCV prevention and treatment
to incidence. The model does however track disease progression of
HCV infections over time.
For both HBV and HCV modelling, we compared the Action
Plan scenario to two other scale-up scenarios: the status quo and
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WHO Elimination 2030 targets. The status quo scenario represented
a ‘no action’ counterfactual—what would happen if no scale-up pro-
gram was launched and only current efforts were sustained. It
assumed there would be no improvements in HBV prevention.
Treatment would be limited to the fewer than 1000 patients cur-
rently being treated for HBV in South Africa, and the fewer than
500 patients being treated for HCV, most of these in one hospital in
Cape Town and the remainder in other major cities.
Since DAAs have not yet been registered with the South African
regulatory authority, these few individuals are currently being
treated as part of clinical trials or compassionate access programs,
importing generic DAAs from India following Medicines Control
Council (MCC) Section 21 approval. These small quantities of
DAAs are either self-funded, funded by provincial hospitals, or via
private health insurance.
The two disease models generate health impacts through five
interventions: improved HBV vaccination coverage through
expanded routine child immunization, HBV birth dose vaccination,
HBV prevention of mother to child transmission (PMTCT), HBV
treatment and HCV treatment. Current coverage of routine child
immunization, including HBV as one antigen of the hexavalent vac-
cine, was estimated at baseline at about 70% in South Africa
(Nayagam et al. 2016c; World Health Organization and UNICEF
2017), and is expected to rise further in the coming years as part of
the ongoing national EPI program. The remaining four interventions
were prioritized by the NDoH Task Force for inclusion in the
Action Plan due to their current low coverage. HBV treatment costs
were assumed to include all direct treatment activities and 50% of
workforce training. HCV treatment costs were assumed to comprise
HCV screening and case finding, treatment itself, and the other 50%
of workforce training.
The main health benefits modelled included reductions in mor-
tality; reduced morbidity from averted cases of advanced liver dis-
ease, including hepatocellular cancer and cirrhosis; and DALYs
averted generated from reductions in mortality and disability
(Murray 1994; World Health Organization 2004; Nayagam et al.
2016b). Since the onset of sequalae associated with chronic hepatitis
is often delayed until later in life, the simulations tracked population
outcomes through 2080 for HBV and 2050 for HCV in order to cap-
ture the long-term benefits of the activities undertaken in the 5-year
Action Plan.
It is reasonable to assume additional benefits would be generated
through the activities in the Action Plan that were not explicitly
modelled, including reduced transmission of hepatitis A and B in
health care facilities, and reduced transmission of hepatitis C in
high-risk populations such as injecting drug users. Quantifying the
deaths and disability averted from these other benefit streams would
further enhance the overall cost-effectiveness of the Action Plan.
Cost-effectiveness analysis and the investment case
We combined our cost estimates and impact analysis to derive selec-
tive value-for-money measures. We estimated the cost-effectiveness
of the benefits of the overall Action Plan and the incremental cost-
effectiveness of each of the four priority interventions (HBV birth
dose vaccination, ANC screening for HBsAg with treatment of
mothers with high risk of transmission to their child and HBV and
HCV treatment). In doing this, we distributed the other cross-
cutting costs of the Action Plan equally across the four
interventions.
Country-specific studies have shown these four interventions to
be generally cost-effective, particularly birth dose vaccination
(Murakami et al. 2008; Klingler et al. 2012). We anticipated similar
results for South Africa, but waited to see the analysis using best
estimates of disease burden and prevailing costs, with particular
focus on the relative impact and cost-effectiveness of the different
interventions, which could help national decision-makers to set pri-
orities within a highly constrained fiscal environment.
To interpret cost-effectiveness and set thresholds for investment
decisions, we expressed the incremental cost-effectiveness ratios
(ICERs) as a percentage of per capita GDP. While no definitive cost-
effective threshold exists for South Africa, recent work suggests that
estimates of less than half of per capita GDP are likely to represent
good value (Woods et al. 2015). Other recent work focusing on the
consumption value of health benefits suggests a somewhat higher
threshold around 1-2 times per capita GDP (Chang et al. 2016;
Robinson et al. 2017). We consider both of these thresholds in our
analysis. In addition, given these diverse views, we provide compari-
sons to alternative uses of additional health resources in South
Africa.
Data sources
Data on the burden of HBV and HCV in South Africa are available
from several studies in the general population and in selected sub-
groups (Burnett et al. 2007; Firnhaber et al. 2008; Lukhwareni et al.
2009; Boyles and Cohen 2011; Andersson et al. 2013; Hatzakis
et al. 2015; Mdlalose et al. 2016).
However, more epidemiological data on HBV and HCV are
urgently needed for South Africa—several surveys and studies are
proposed as part of the Action Plan, including an analysis of hepati-
tis prevalence in pregnant women as part of South Africa’s long-
established HIV antenatal seroprevalence surveillance. Data on unit
costs for public awareness, training, surveillance, screening,
counselling and lab tests were obtained from government institu-
tions including the National Institute for Communicable Diseases,
published sources such as the NDoH price list (South Africa
National Department of Health 2016), comparable unit costs from
the well-documented South Africa HIV program, and other hepatitis
modelling studies for South Africa (Fraser et al. 2016). Hepatitis B
monovalent immunization costs were based on the prices of vac-
cines, consumables, and service delivery costs from UNICEF and the
South Africa EPI program. The costs of hepatitis medicines were
based on the current tender prices for tenofovir and interferon ther-
apy for HBV, and on the price for DAAs for HCV as listed by
Gilead Sciences for LMICs in its generic zone.
Licensees of Gilead have been selling DAAs at lower prices in
other LMICs, but as of yet they have not registered their products in
South Africa. Follow-on analysis could assess the additional savings
possible through reduced DAA prices, which would generate lower
and more attractive ICERs.
Results
Scope
Based on the consultations described above, it was decided that the
Action Plan would cover a wide range of activities to prevent and
treat HBV and HCV in South Africa.
Given anticipated fiscal and human resource capacity con-
straints, moderate coverage targets for HBV and HCV treatment
were chosen, below the levels required to achieve the WHO global
goals for 2030 (World Health Organization 2016b). Activities that
are already ongoing, such as HBV childhood immunization, were
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deemed important but were not included in the Action Plan since
they are already operating at scale.
The Action Plan consisted of five main priority areas (Table 1):
1. Awareness Raising among the health work force and general
population: information campaigns, training of health workers.
2. Strengthening Knowledge of disease burden: surveillance, sur-
veys and special studies.
3. Prevention of Viral Hepatitis: protection of health care workers,
HBV vaccine birth dose and PMTCT.
4. Testing, Care, and Treatment: screening, diagnosis, linkage to
care, and drug therapy for HBV and HCV.
5. Management and Coordination: program management, moni-
toring and evaluation, and policy development.
Cost and affordability
The overall cost of the 5-year Action Plan was estimated to be
ZAR3.78 billion (US$270 million). The costliest part of the Action
Plan was the testing, care, and treatment component, accounting for
about ZAR2.47 billion (US$177 million) or 65% of the total, fol-
lowed by prevention (15%), awareness raising (11%), strengthening
knowledge (6%) and management and coordination (2%).
Among the high impact investments, HBV birth dose vaccination
and PMTCT were estimated to cost ZAR512 million (US$36.5 mil-
lion), a one-time campaign to screen and vaccinate health workers
would absorb ZAR56 million (US$4.0 million), and initial scale up
of HCV and HBV treatment would require ZAR594 million
(US$42.4 million) and ZAR1.66 billion (US$114.2 million), respec-
tively, over 2017–2021 (Table 2).
Our fiscal analysis suggests that investments under the Hepatitis
Action Plan amounts to an average of about 0.5% of the total
ZAR771 billion (US$55.0 billion) projected government expendi-
tures for health during 2017–2021. Based on the Government’s own
forecast of modest growth of the South African budget of 3.5% over
this period, the required outlays under the Action Plan would absorb
an average of 14% of the anticipated increment in government
spending.
To put the estimated price tag for the Action Plan in perspective,
South Africa currently spends nearly ZAR19 billion (US$1.36 bil-
lion) annually to combat HIV and AIDS (South Africa National
AIDS Council 2017). The cost of the Hepatitis Action Plan thus rep-
resents <4% of the funds that the South African Government
expects to devote to HIV over the next 5 years.
Impact
Using our disease models, we found that the investments outlined in
the Action Plan, if sustained during the 5-year period and beyond,
can have a major impact on the HBV and HCV burden of disease in
South Africa.
Under the status quo, we estimated that 1.1 million new HBV
infections would occur over the next six decades until 2080, with
393 000 HBV-related deaths and losses of 15 million DALYs. By
investing in the Action Plan over the next 5 years, 10% of these
losses would be averted. Going beyond this start to reach the ambi-
tious WHO targets (30% reduction in new infections by 2020, 90%
by 2030) would avert up to 30% of the losses expected under the
status quo.
Although not explicitly included in the Action Plan, improving
the coverage of South Africa’s routine child vaccination program
(currently at about 70% (Nayagam, et al. 2016c; World Health
Organization and UNICEF 2017)) to 90% was estimated to result
in a 25% reduction in new HBV infections, as compared with the
status quo.
Adding birth dose vaccination (within 24 h of birth) to 90% cov-
erage levels would avert another 35% of new infections, and screen-
ing of pregnant women and tenofovir treatment for those found to
be HBV-infected would lead to a further 3% drop in incidence.
The combined effect of these measures was thus estimated to lower
new infections by 63% over the next 60 years.
Implementing the 5-year effort to begin screening and treating
South Africans with chronic HBV during 2017–2021 would avert
an additional 13 000 liver disease-related deaths, including 2000
cases of liver cancer, and result in a savings of an additional 66 000
discounted DALYs compared to only the prevention activities.
Sustaining this effort and increasing the pace of scale up to achieve
the WHO goals by 2030—assuming that this is feasible for South
Africa in terms of fiscal and human resource capacity—would multi-
ply these initial gains 15-fold, averting nearly 200 000 deaths and
over 31 000 cases of liver cancer.
The proposed initial five-year scale up of HCV treatment of
15 500 patients would result in up to an estimated 7145 additional
deaths averted and 64 000 DALYs saved as compared with the sta-
tus quo, depending on the targeting strategy. If this early effort was
sustained to enable South Africa to achieve the WHO goal of elimi-
nation by 2030, the country could avert over 30 000 HCV-related
deaths.
Cost-effectiveness
Our analysis suggests an overall cost-effectiveness ratio of US$3310
(ZAR46 373) per DALY averted for the full Action Plan, demon-
strating acceptable value-for-money, as this ratio is just below
benchmark of half per capita GDP (South Africa’s 2015 GDP per
capita¼US$7620) (Table 3). While the Action Plan’s cost-
effectiveness profile is less favourable than that of some key pro-
grams in South Africa, such as AIDS treatment and TB treatment
(Meyer-Rath et al. 2017; Tufts Medical Center 2018), it is similar to
other health interventions under consideration for implementation
in South Africa including: pre-exposure prophylaxis for HIV: $2700
per life year saved (Walensky et al. 2012); strategies for rural
community-based TB/HIV screening and linkage: $1700–$3400 per
life year saved (Gilbert et al. 2016); screening for TB in HIV
patients: $2800 per life year saved for sputum smear, $5100 per life
year saved for Xpert/RIF (Andrews et al. 2012); and a diabetes edu-
cation program: $1862 per QALY gained (Mash et al. 2015).
Among the individual interventions, HBV birth dose was the
best buy at US$329 (ZAR4609) per additional DALY averted com-
pared to the status quo. The ICERs for HCV and HBV treatment
were US$2849 (ZAR39 914) and US$5021 (ZAR70 344) per addi-
tional DALY averted, respectively (Table 3). The current estimates
are based on no restrictions on treatment eligibility, but if South
Africa pursued a more targeted approach focusing on more
advanced patients, HCV treatment could become more cost-
effective.
PMTCT was found to be the least cost-effective impact interven-
tion [ICER of US$26 241 (ZAR367 636) per DALY averted]
(Table 3). However, PMTCT was not removed from the analysis,
because it was the main source of case finding for the HBV treat-
ment program in the Action Plan. Thus, when it is bundled with
HBV treatment, the ICER for the combined package of PMTCT and
HBV treatment was a more reasonable US$5531 (ZAR77 489) per
DALY averted.
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Discussion
The modelling and analysis of the costs, financing, expected impact,
and cost-effectiveness of the proposed 2017–2021 South African
National Hepatitis Action Plan suggests that South Africa can
mount an expanded response to HBV and HCV at an affordable
cost and in a cost-effective manner. Even if a wide range of demand
generation, surveillance, prevention and treatment activities are
undertaken, the financial resources required amount to ZAR3.78
billion over 5 years, or around 0.5% of all projected government
health spending in South Africa. The modelled impact of this first
5-year investment is significant, at 13 000 deaths averted from HBV
and another 7000 from HCV. The Action Plan investments put
South Africa on the path to a large-scale reduction of HBV and
HCV, with the potential to avert >672 000 HBV infections and save
a total of 60 000 lives from liver-related disease caused by HCV
if the treatment program continues to expand and achieves
elimination by 2030, as proposed by WHO (World Health
Organization 2016b).
If South Africa is unable to mobilize the full funding require-
ments for the Action Plan because of fiscal pressures, our analysis
shows how it can nevertheless target a sub-set of priority activities
with important benefits. Implementing HBV birth dose vaccination
should be the first priority, based on the highest cost-effectiveness
and low budgetary cost of ZAR46 million (US$3.3 million) over
5 years. HCV and HBV treatment could then be phased in, starting
with the modest coverage suggested in the Action Plan and expand-
ing progressively over time.
HBV PMTCT as a standalone prevention activity was not found
to be convincingly cost-effective, but should still be considered for
inclusion in the overall program since PMTCT screening is currently
the main source of HBV case finding, and can be phased in rapidly
as an add-on to the existing nationwide PMTCT program for HIV.
PMTCT can also serve as a safety net to prevent vertical
Table 2. Cost breakdown by Action Plan priority areas and objectives (in ZAR millions)
2017 2018 2019 2020 2021 ZAR M (USD M)
Priority Area 1 Raise awareness of hepatitis infection 76 89 100 77 92 434 (31)
Objective 1a Raise awareness among health care workers of
Hepatitis burden and risk, and SA’s new national
guidelines
0.1 0 0.04 0 0.04 0.2
Objective 1b Train HCWs to deliver guideline-concordant care for
viral hepatitis prevention, diagnosis and treatment
6 6 6 6 6 30
Objective 1c Coordinated national campaign to build awareness
among the general public & high-risk communities
70 84 94 71 85 404
Priority Area 2 Strengthen knowledge of hepatitis burden of disease 45 92 3 103 0.8 244 (18)
Objective 2a Track prevalence of hepatitis infection in general and
sub-populations
44 92 2 102 0 240
Objective 2b Improve surveillance systems and laboratory capacity 0.4 0.6 0.7 0.8 0.8 3
Priority Area 3 Prevent transmission of viral hepatitis 9 12 164 175 208 568 (41)
Objective 3a Minimize risk of Hep A & B transmission risk in
healthcare facilities
2 2 46 3 3 56
Objective 3b Prevent vertical transmission of HBV 8 10 118 172 205 512
Priority Area 4 Improve diagnosis and treatment of chronic hepatitis 107 202 390 703 1071 2473 (177)
Objective 4a Routing screening for HBV and HCV in target
populations
0 0 7 22 33 62
Objective 4b Expand access to treatment for mono-infected CHB 74 147 274 480 686 1661
Objective 4c Expand access to treatment for CHC 18 38 76 154 308 594
Objective 4d Training programs to increase hepatology trained
workforce
15 17 33 48 45 157
Priority Area 5 Management, coordination, and evidence-based policy 8 10 12 14 15 59 (4)
Objective 5a Ensure integration of Hepatitis efforts into HIV, TB
and other related efforts within the DOH
5 7 9 11 11 44
Objective 5b Undertake M&E and strategic information manage-
ment within the NDOH Hepatitis Unit
2 2 2 2 2 9
Objective 5c Undertake supervision, quality control and technical
support visits to PDOHs and treatment facilities
0.6 0.7 1 1 1 5
Objective 5d Develop and promote a research agenda for hepatitis 0.1 0.1 0.1 0.2 0.2 0.7
Total ZARM (USDM) 245 (18) 405 (29) 670 (45) 1074 (70) 1387 (88) 3781 (249)
Note: Rows and columns may not sum to total amounts due to rounding.
Table 3. Cost-effectiveness of South Africa National Hepatitis
Action Plan interventions
Intervention Incremental
DALYs
averted
Incremental
cost (USD Millions,
discounted 3%)
ICER (USD
Millions per
additional DALY
averted)
Status Quo - - -
Birth Dose 47 185 $15.5 $329
HCV Treatment 20 822 $59.3 $2849
HBV Treatmenta 66 191 $332.3 $5021
PMTCT 1612 $42.3 $26 241
Overall 135 810 $449.5 $3310
aAnalysis accounts for the lifelong tenofovir treatment for surviving HBV
patients, while the costs for HBV treatment described in Table 2 only cover
the 5-year cost of the Action Plan.
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transmission if birth dose implementation falters and is a gateway to
treatment for young women identified through screening.
The proposed targets for HCV treatment with DAAs, which
have a cure rate of over 95% based on three months of daily oral
drug therapy, carry a price tag of ZAR600 million (US$42.4 million)
for the first 5 years of program start-up. Assuming that other con-
straints including health workforce capacity and regulatory appro-
vals can be addressed (see below), such an HCV treatment effort to
reach the first 15 500 South Africans with DAAs is both feasible and
can yield useful lessons in how to organize and prepare for scale-up.
Affordability of HCV treatment could be further enhanced if South
Africa obtains DAAs at competitive generic prices. Our modelling
assumed a current ‘ceiling’ price of US$900 per cure offered by the
originator company in the generic zone to which South Africa
belongs. Prices as low at $200–$450 per cure are being reported
from India and Egypt, where generic licensees are competing with
each other. South Africa may be able to procure DAAs at prices in
this range (World Health Organization 2017).
HBV treatment scale up was also estimated to be cost-effective,
based on the low cost of the generic form of the recommended drug
of choice (tenofovir). The large burden of HBV disease (6–7% in the
general population) also argues in favour of launching a treatment
program. However, given the relatively large share of HBV treat-
ment in the overall cost of the Action Plan and the more complex
and demanding requirements for patient staging, diagnosis and
monitoring, this could be an area where South Africa proceeds more
slowly in the next few years if it is unable to pursue all of the invest-
ments in the Action Plan simultaneously.
The feasibility of implementing the Action Plan may be enhanced
if South Africa builds its hepatitis program on the backbone of the
existing health system, especially the parts of the system that have
been strengthened over the past two decades to address maternal
and child health and HIV/AIDS. A new birth dose vaccination com-
ponent can be inserted into the current post-partum services being
offered in health facilities, including the BCG vaccine that is given at
birth. The screening and antiviral treatment for HBV-positive preg-
nant women can be added on to antenatal services that already
screen and use anti-retroviral prophylaxis for HIV-positive pregnant
women in South Africa (up to 30% of these women are testing HIV
positive). Screening for HBV and HCV can also be added on to
existing screening, counselling, and referral services for HIV and
tuberculosis that have been decentralized to primary health care
facilities and special programs catering to high risk sub-populations,
such as opioid substitution therapy. The latter could improve the
targeting of HCV screening, since emerging evidence suggests a
higher prevalence of hepatitis among injecting drug users and other
high-risk groups (Scheibe et al. 2017).
Even if the financial resources for the Action Plan can be success-
fully mobilized in South Africa, other important non-financial bar-
riers will have to be addressed. The shortage of trained health
workers is one of the most pressing. At the lower levels of the health
system, South Africa’s community health workers, nurses and pri-
mary care physicians will need to be trained to do HBV/HCV test-
ing, counselling, initiation of treatment and patient monitoring.
At the upper end of the health system, there is an acute shortage of
hepatologists and gastroenterologists—South Africa currently has
just a handful of hepatologists who can help to design treatment
protocols, train generalist doctors and manage complex cases.
Programs such as the ECHO project (University of New Mexico
School of Medicine 2017) or simplification of treatment protocols
so that general practitioners can treat HBV and HCV patients, could
be adopted to ease this constraint.
The other issue is the slowness of the South African drug regula-
tory authority to register DAAs for HCV treatment. At present, it is
taking more than 2 years to register the first originator products.
The dossier for Gilead’s Sovaldi was submitted in 2014 and appro-
val is expected shortly. However, the file for Harvoni had to be re-
submitted in late 2016, and approval was not anticipated for at least
18 months. The other originator products from Merck and Abbvie
have not yet been submitted to the MCC. Generic versions of these
drugs cannot be registered until after the originator product has
been approved. Expedited action by the MCC could overcome this
key remaining barrier to large-scale treatment.
While the cost and impact modelling results presented here are
solidly grounded on the best available data, there are limitations to
our analysis. Our proposed coverage levels and modelled impacts of
prevention and treatment interventions are based on assumed HBV
and HCV prevalence, which is still poorly understood for South
Africa. More surveillance and epidemiological data (seroprevalence
and risk factor surveys of the general population, children and preg-
nant women and high-risk groups) are needed. Due to the disease
model design, the HCV health impact estimates do not account for
changes in incidence over time due to scaled-up treatment and thus
reductions in transmission within at-risk populations. However, in
South Africa, where most HCV infections occurred in the past due
to unsafe blood transfusions and possible unsafe traditional practi-
ces, this feedback loop may be less important, even though there is
mounting evidence of some new HCV infections taking place within
vulnerable groups, including injecting drug users and men having
sex with men (Scheibe et al. 2017). Our cost estimates could also
benefit from further data collection and validation—a national hep-
atitis unit cost database, regularly updated, would be a helpful addi-
tion to our existing knowledge foundation and could help support
future planning efforts.
For HCV drugs, we used current prices charged by the originator
company in its generic territories (US$900 for ledipasvir/sofosbuvir)
and for most lab tests we relied on the prices listed by the National
Health Laboratory Services. In both drugs and diagnostics, we
expect prices to fall over time as generic competition increases and
volumes grow. This will make the Action Plan less costly and
enhance cost-effectiveness further. Our analysis could then need to
be updated to incorporate these efficiency gains.
The modelling suite we used provides a decision-making instru-
ment for other LMIC governments and potential donors. Next steps
would be adding a user-friendly interface to the disease modelling
component and enhancements to the costing tool to make is more
accessible to first-time users.
The South African experience with the Hepatitis Action Plan
has important implications for hepatitis policy development. Using
an investment case framework, expanded HBV prevention and
drug therapy and HCV treatment using the new DAA cures appear
to be cost-effective and affordable for South Africa, and this con-
clusion may apply to other countries. If this turns out to be the
case, hepatitis control and elimination efforts may emerge as prior-
ities for future investment, even in LMICs where donor financial
support is unlikely to materialize. However, cost-effectiveness and
affordability need to be demonstrated in each unique country using
locally available data, and neither cost-effectiveness nor afford-
ability can be assumed from the outset. There may be national cir-
cumstances of low HBV/HCV prevalence where it is difficult and
costly to screen and treat those infected with HBV/HCV, and here
an investment case analysis could suggest that hepatitis scale up
should not be treated as a priority unless ways are found to make
the program more efficient.
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In addition, our work demonstrates that the investment case
approach, through adapting existing methods while developing new
tools for hepatitis, is an appropriate and fruitful method for con-
ducting feasibility analysis and engaging national and international
stakeholders in an evidence-based discussion of the advisability of
pursuing a range of scenarios for scaling up HBV/HCV programs.
A number of the process elements used in South Africa—
including forming a national working group; linking the develop-
ment of national clinical guidelines with a 5-year action plan and
longer-term modelling of scale up; and then bringing the emerging
results to the health ministry leadership and a joint health–finance
consultative discussion—were productive and could be adopted by
other countries.
As growing numbers of countries consider pursuing the WHO
goals for HBV/HCV elimination by 2030, the investment case
approach that we piloted in South Africa may offer useful lessons on
the tools, techniques and engagement process that could be pursued
elsewhere to design and adopt national hepatitis programs and
mobilize the needed resources to prevent disease and save lives.
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